{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:02:24Z","timestamp":1793109744792,"version":"4.5.0"},"reference-count":23,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2022,10,1]]},"abstract":"Importance<\/jats:title>Drug survival of biologic therapies for psoriasis is a proxy for longer-term treatment effectiveness and safety. Patient factors that are associated with the survival of each biologic differently (effect modifiers) may inform the decision to choose between biologics.<\/jats:p><\/jats:sec>Objective<\/jats:title>To assess the drug survival associated with the effectiveness and safety of commonly used biologics for psoriasis in the UK and Ireland and identify effect modifiers for these biologics and their survival.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>We conducted a prospective cohort study of patients with psoriasis using data from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) between November 2007 and August 2021.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Adalimumab, ustekinumab, secukinumab, guselkumab, ixekizumab.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>We conducted a survival analysis and fitted separate flexible parametric models for drug survival as a proxy for effectiveness and safety.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 16\u202f122 treatment courses were included: 6607 (41.0%) in which treatment with adalimumab was initiated, 5405 (33.5%) with ustekinumab, 2677 (16.6%) with secukinumab, 730 (4.5%) with guselkumab, and 703 (4.4%) with ixekizumab. The crude survival functions at year 1 for measures of effectiveness for treatment with adalimumab was 0.81 (95% CI, 0.80-0.82), 0.89 for ustekinumab (95% CI, 0.88-0.89), 0.86 for secukinumab (95% CI, 0.85-0.87), 0.94 for guselkumab (95% CI, 0.92-0.96), and 0.86 for ixekizumab (95% CI, 0.83-0.89). The adjusted survival curves from the multivariable model for effectiveness showed that treatment with guselkumab had the higher survival (adjusted hazard ratio, 0.13; 95% CI, 0.03-0.56) and adalimumab had the lower survival (adjusted hazard ratio, 2.37; 95% CI, 2.03-2.76) compared with ustekinumab. Secukinumab and ixekizumab had similar survival curves over time. Psoriatic arthritis, previous biologic exposure, nail involvement, and ethnicity were effect modifiers for survival in association with treatment effectiveness. The crude survival functions at year 1 for safety were 0.91 for treatment with adalimumab (95% CI, 0.90-0.91), 0.94 for ustekinumab (95% CI, 0.94-0.95), 0.94 for secukinumab (95% CI, 0.92-0.94), 0.96 for guselkumab (95% CI, 0.94-0.98), and 0.92 for ixekizumab (95% CI, 0.89-0.94). Guselkumab, ustekinumab, and secukinumab had similar adjusted survival curves for safety, while adalimumab (adjusted hazard ratio, 1.66; 95% CI, 1.46-1.89) and ixekizumab (adjusted hazard ratio, 1.52; 95% CI, 1.13-2.03) had lower survival compared with ustekinumab.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>The results of this cohort study suggest that guselkumab had the highest drug survival in BADBIR of the included biologics for treatment persistence that was associated with effectiveness, and guselkumab had highest drug survival for safety compared with other biologics except ustekinumab. Psoriatic arthritis, nail involvement, previous biologic exposure, and ethnicity were effect modifiers for biologics and their survival in association with treatment effectiveness. This information on longer-term treatment persistence, safety, and tolerability may help patients and their clinicians make an informed decision to initiate treatment with a biologic therapy.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamadermatol.2022.2909","type":"journal-article","created":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T09:30:38Z","timestamp":1657099838000},"page":"1131","source":"Crossref","is-referenced-by-count":146,"title":["Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis"],"prefix":"10.1001","volume":"158","author":[{"given":"Zenas Z. N.","family":"Yiu","sequence":"first","affiliation":[{"name":"Centre for Dermatology Research, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester Academic Health Science Centre, National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre, Manchester, England"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Becher","sequence":"additional","affiliation":[{"name":"West Glasgow Ambulatory Care Hospital, Glasgow, Scotland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Kirby","sequence":"additional","affiliation":[{"name":"Charles Department of Dermatology, St Vincent's University Hospital, Dublin, Ireland and School of Health Sciences and Charles Institute, University College Dublin, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Laws","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The Leeds Teaching Hospitals NHS Trust, Leeds, England"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick J.","family":"Reynolds","sequence":"additional","affiliation":[{"name":"Institute of Translational and Clinical Medicine, Newcastle University Medical School and Department of Dermatology and the Newcastle NIHR Biomedical Research Centre, Royal Victoria Infirmary, Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, England"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine H.","family":"Smith","sequence":"additional","affiliation":[{"name":"St Johns Institute of Dermatology, NIHR Biomedical Research Centre, Guys & St Thomas NHS Foundation Trust, Kings College London, London, England"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Warren","sequence":"additional","affiliation":[{"name":"Centre for Dermatology Research, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester Academic Health Science Centre, National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre, Manchester, England"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher E. M.","family":"Griffiths","sequence":"additional","affiliation":[{"name":"Centre for Dermatology Research, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester Academic Health Science Centre, National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre, Manchester, England"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"BADBIR Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Browne","sequence":"additional","affiliation":[{"name":"for the BADBIR Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Evans","sequence":"additional","affiliation":[{"name":"for the BADBIR Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Kleyn","sequence":"additional","affiliation":[{"name":"for the BADBIR Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Lawson","sequence":"additional","affiliation":[{"name":"for the BADBIR Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"McElhone","sequence":"additional","affiliation":[{"name":"for the BADBIR Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teena","family":"Mackenzie","sequence":"additional","affiliation":[{"name":"for the BADBIR Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tess","family":"McPherson","sequence":"additional","affiliation":[{"name":"for the BADBIR Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Murphy","sequence":"additional","affiliation":[{"name":"for the BADBIR Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Owen","sequence":"additional","affiliation":[{"name":"for the BADBIR Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor","family":"Pearson","sequence":"additional","affiliation":[{"name":"for the BADBIR Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josh","family":"Richards","sequence":"additional","affiliation":[{"name":"for the BADBIR Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lunt","sequence":"additional","affiliation":[{"name":"for the BADBIR Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Burden","sequence":"additional","affiliation":[{"name":"for the BADBIR Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oras","family":"Alabas","sequence":"additional","affiliation":[{"name":"for the BADBIR Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Morrison","sequence":"additional","affiliation":[{"name":"for the BADBIR Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shernaz","family":"Walton","sequence":"additional","affiliation":[{"name":"for the BADBIR Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Bewley","sequence":"additional","affiliation":[{"name":"for the BADBIR Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shehnaz","family":"Ahmed","sequence":"additional","affiliation":[{"name":"for the BADBIR Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lillie","family":"Turnbull Jones","sequence":"additional","affiliation":[{"name":"for the BADBIR Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Symons","sequence":"additional","affiliation":[{"name":"for the BADBIR Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Barker","sequence":"additional","affiliation":[{"name":"for the BADBIR Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Hampton","sequence":"additional","affiliation":[{"name":"for the BADBIR Study Group"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"doi220037r1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011535.pub4","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.","volume":"4","author":"Sbidian","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"doi220037r2","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1001\/jamadermatol.2018.0183","article-title":"Comparison of drug discontinuation, effectiveness, and safety between clinical trial eligible and ineligible patients in BADBIR.","volume":"154","author":"Mason","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"1","key":"doi220037r3","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1001\/jamadermatol.2020.4202","article-title":"Randomized trial replication using observational data for comparative effectiveness of secukinumab and ustekinumab in psoriasis: a study from the British Association of Dermatologists Biologics and Immunomodulators Register.","volume":"157","author":"Yiu","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"2","key":"doi220037r4","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/bjd.v183.2","article-title":"Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).","volume":"183","author":"Yiu","year":"2020","journal-title":"Br J Dermatol"},{"issue":"3","key":"doi220037r5","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.jaad.2021.06.878","article-title":"Comparison of two-year treatment adherence, persistence, discontinuation, reinitiation, and switching between psoriasis patients treated with ixekizumab or secukinumab in real-world settings.","volume":"86","author":"Blauvelt","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"doi220037r6","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s40257-021-00598-4","article-title":"Drug survival of IL-12\/23, IL-17 and IL-23 inhibitors for psoriasis treatment: a retrospective multi-country, multicentric cohort study.","volume":"22","author":"Torres","year":"2021","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"doi220037r7","doi-asserted-by":"publisher","DOI":"10.1111\/dth.v34.2","article-title":"Drug survival of ixekizumab, TNF inhibitors, and other IL-17 inhibitors in real-world patients with psoriasis: the Corrona Psoriasis Registry.","volume":"34","author":"Lockshin","year":"2021","journal-title":"Dermatol Ther"},{"issue":"6","key":"doi220037r8","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1111\/bjd.v184.6","article-title":"Biologic drug survival rates in the era of anti-interleukin-17 antibodies: a time-period-adjusted registry analysis.","volume":"184","author":"Graier","year":"2021","journal-title":"Br J Dermatol"},{"issue":"3","key":"doi220037r9","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/bjd.2012.166.issue-3","article-title":"The British Association of Dermatologists\u2019 Biologic Interventions Register (BADBIR): design, methodology and objectives.","volume":"166","author":"Burden","year":"2012","journal-title":"Br J Dermatol"},{"issue":"2","key":"doi220037r10","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/bjd.2015.173.issue-2","article-title":"Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register.","volume":"173","author":"Iskandar","year":"2015","journal-title":"Br J Dermatol"},{"issue":"11","key":"doi220037r11","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1038\/jid.2015.208","article-title":"Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).","volume":"135","author":"Warren","year":"2015","journal-title":"J Invest Dermatol"},{"issue":"3","key":"doi220037r12","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/bjd.v181.3","article-title":"Factors predicting persistence of biologic drugs in psoriasis: a systematic review and meta-analysis.","volume":"181","author":"Mourad","year":"2019","journal-title":"Br J Dermatol"},{"issue":"15","key":"doi220037r13","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1002\/(ISSN)1097-0258","article-title":"Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects.","volume":"21","author":"Royston","year":"2002","journal-title":"Stat Med"},{"issue":"25","key":"doi220037r14","doi-asserted-by":"publisher","first-page":"3298","DOI":"10.1002\/sim.v34.25","article-title":"Combining fractional polynomial model building with multiple imputation.","volume":"34","author":"Morris","year":"2015","journal-title":"Stat Med"},{"issue":"1","key":"doi220037r15","doi-asserted-by":"publisher","first-page":"4741","DOI":"10.1038\/s41467-021-25066-9","article-title":"Enhanced NF-?B signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis.","volume":"12","author":"Andres-Ejarque","year":"2021","journal-title":"Nat Commun"},{"issue":"8","key":"doi220037r16","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1016\/j.jid.2021.02.746","article-title":"Meeting report: psoriasis stratification to optimize relevant therapy showcase.","volume":"141","author":"Yiu","year":"2021","journal-title":"J Invest Dermatol"},{"issue":"5","key":"doi220037r17","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/bjd.2019.180.issue-5","article-title":"Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study.","volume":"180","author":"Warren","year":"2019","journal-title":"Br J Dermatol"},{"issue":"2","key":"doi220037r18","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/bjd.v182.2","article-title":"Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study.","volume":"182","author":"Reich","year":"2020","journal-title":"Br J Dermatol"},{"issue":"10","key":"doi220037r19","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1016\/j.jid.2018.04.019","article-title":"Ixekizumab pharmacokinetics, anti-drug antibodies, and efficacy through 60 weeks of treatment of moderate to severe plaque psoriasis.","volume":"138","author":"Reich","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"2","key":"doi220037r20","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1080\/09546634.2018.1473552","article-title":"Systematic review of anti-drug antibodies of IL-17 inhibitors for psoriasis.","volume":"30","author":"Thomas","year":"2019","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"doi220037r21","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/bjd.2018.178.issue-1","article-title":"Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial.","volume":"178","author":"Langley","year":"2018","journal-title":"Br J Dermatol"},{"issue":"1","key":"doi220037r22","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jaad.2019.03.048","article-title":"Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis.","volume":"81","author":"Egeberg","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"doi220037r23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/bjd.2019.180.issue-1","article-title":"How real are \u2018real-life studies\u2019 in psoriasis, and the uncertain meaning of drug persistence.","volume":"180","author":"Garcia-Doval","year":"2019","journal-title":"Br J Dermatol"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2794033\/jamadermatology_yiu_2022_oi_220037_1668541467.00045.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T16:01:57Z","timestamp":1668614517000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2794033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,1]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2022.2909","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,1]]}}}